Rewired.GG Makes Europe’s Largest Ever esports Team Investment
7.11.2019 10:00:00 EET | Business Wire | Press release
Rewired.GG, the €50m esports venture fund that invests in the global growth of esports, is delighted to announce that it has invested a further €14 million into Team Vitality, taking its total investment to date to €34 million. Today also marks the opening of the new multi-million euro Team Vitality headquarters in Paris, called V.Hive, which will be open to the public. In a world’s first for an esports team, the 10,700 sq ft V.Hive has more than 530 sq ft of store front in the bustling heart of Paris, and will offer engaging esports discoveries and experiences to anyone who walks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191106005183/en/
Team Vitality Counter Strike players (from left to right): Alex 'ALEX' McMeekin, Cédric 'RpK' Guipouy, Mathieu 'ZywOo' Herbaut, Dan 'apEX' Madesclaire. (Photo: Business Wire)
Team Vitality is one of the biggest esports teams in Europe and boasts some of the world’s top esports players and coaches. It is one of only ten European esports teams in the League of Legends European Championship franchise; and has recently won the 2019 World Championship for Rocket League, won the 7th season of the prestigious ECS tournament for Counter-Strike:Global Offensive and took 3rd place in the 2019 FIFA World Championship. It is also one of only a few esports teams with blue chip sponsors such as Orange, Renault, Red Bull and adidas.
Rewired.GG forecasts that esports will rival traditional sports such as soccer and basketball and will be a major investment category for institutional investors, funds and investment managers. By 2020 it is estimated that the monthly global esports audience size will be nearly 600 million*, equivalent to the current global audience of the English Premier League.
Today’s investment, along with the €20 million that Team Vitality received from Rewired.GG in November 2018, is thought to be the largest investment into a European esports team to date. The Team, which was founded in 2013 with €10,000, aims to be one of the world’s first $1 billion esports teams.
The funds will be used to support the continued growth of Team Vitality as the team pursues further expansion across India and China, where it is acquiring new players and launching a network of esports academies. Funds will also be used to acquire new players and to launch new lines of merchandise globally: as well as opening V.Hive, the team has also today launched its first Team Vitality brand of limited-edition adidas trainers.
As with any major sport, the business of esports is based on media rights, advertising, prize money, merchandise, sponsorship and partnerships. Revenue from these are growing exponentially.
In 2017 it was estimated that esports generated $655 million in annual revenue, including 38% from sponsorships and 14% from media rights. By 2022, it is forecast that media rights will reach 40% of total esports revenue and that total global esports monetization will reach $3bn.*
CEO of Team Vitality, Nicolas Maurer said:
“In 2013 we started Team Vitality with €10,000. Today Team Vitality has built amazing teams that regularly win tournaments all over the world, and a strong brand that is backed by our amazing and dedicated fans and our premium sponsors. Receiving further backing by Rewired.GG after the initial investment of €20M in November 2018 is a testament to the strength not only of the team but also a comment on the growth of the sector as a whole. This investment will go towards continuing to turn Team Vitality into a global esports brand and we look forward to providing further updates on our future wins as we continue to pursue V for Victory.”
Amit Jain, Principal at Rewired.GG commented:
“Any industry with an audience that’s growing rapidly into hundreds of millions is hugely exciting and esports is no exception. We’ve seen the current esports trend many times before in the tech sector: first the number of eyeballs grows exponentially, and then full monetization comes later. We believe that esports is one of the world’s fastest growing industries today, and the success of teams like Team Vitality show that there is real opportunity for growth in this market. We are well on the way to building one of the world’s first billion-dollar esports teams.”
-ends-
Footnotes and References
*BBC
Video of esports world champion, Rocket League player Kyle ‘Scrub Killa’ Robertson, and esports super-coach Mike ‘Gregan’ Ellis, are available to embed into stories relating to this release, using these links:
Gregan: https://youtu.be/uLN4S1LFVgI
Scrub Killa: https://youtu.be/LSg-rwTeBHk
Images are available to download here and must be attributed to: Team Vitality: https://drive.google.com/drive/folders/1Ol4_J_pdo8S7c6W-YZ8tkgTrfOFPd4Xd
About Rewired.GG
Rewired.GG is an esports venture fund investing in the talent and ideas that are driving the global growth of esports. In November Rewired.GG 2018 backed European esports leader Team Vitality with €20m of investment to create a global esports brand. The investment thesis of the Rewired.GG esports venture fund is that esports is at an exciting tipping point. The NFL earns around $50 per fan, but that number for esports is only $3.20*. Rewired.GG predicts that this upside potential revenue growth per fan combined with rapidly growing global audiences with rapidly-growing spending power, will generate significant future returns.
About Team Vitality
Team Vitality is an international esports organisation that was founded by Nicolas Maurer and Fabien Devide in 2013. The team has players from ten different nationalities and boasts some of the biggest players in the world, including the world No.1 Fifa player, world No.1 CS:GO player, and the world champion Rocket League squad. Team Vitality players compete in a portfolio of 9 games with 10 competitive teams. Team Vitality's main League of Legends roster competes in the League of Legends European Championship (LEC), which they joined after purchasing Gambit Gaming's spot. They are sponsored by Orange, Red Bull, Renault and Adidas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005183/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff (Buchanan Communications)
rewired@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom